The Clinical Center of the University of Sarajevo (KCUS) informed the public about extremely important facts regarding the lack of cytostatics necessary for the treatment of oncology patients, which is why the Federation of Bosnia and Herzegovina (FBiH)’s Health Insurance and Reinsurance Institute was contacted.
KCUS informed the public two months ago and pointed out the problem of the lack of very important drugs used in chemotherapy, and considering that the Health Insurance and Reinsurance Institute of the FBiH is in charge of their procurement, they accused that they, i.e. the institute, were to blame for the shortage of drugs.
Earlier, it was written about the lack of lenalidomide, a type of cytostatic drug used by leukemia patients. Then the Institute confirmed that there was a problem with the suppliers who deliver the medicine to KCUS, which caused delays and thus a shortage of medicine at the clinical institution.
In the middle of last month, the Institute informed the public that due to disruptions in the market, there was a delay in the delivery of certain medicines, for which the Institute will refund procurement costs until the supply is normalized.
Disruption in the world drug market is not something that BiHcan influence, but as with many processes, we also suffer the consequences of global trends. However, one has to put an end to it so that there are no worst-case scenarios when it comes to medicines.
Any medical institution or health institute is obliged to provide patients with adequate and complete therapy, Klix.ba reports.
E.Dz.
